Key statistics
As of last trade, SpringWorks Therapeutics Inc (SWTX:NSQ) traded at 32.53, 80.69% above the 52 week low of 18.00 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.73 |
---|---|
High | 33.19 |
Low | 32.22 |
Bid | 32.47 |
Offer | 32.57 |
Previous close | 32.64 |
Average volume | 920.32k |
---|---|
Shares outstanding | 74.27m |
Free float | 71.12m |
P/E (TTM) | -- |
Market cap | 2.42bn USD |
EPS (TTM) | -4.44 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 17:16 BST.
More ▼
Announcements
- FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
- SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
- SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
- SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
- SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
- SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
More ▼